A fund reduced its Viridian Therapeutics holdings by 238,243 shares, cutting exposure before a June 30 FDA catalyst.
HighVista Strategies sold 238,243 shares of Viridian Therapeutics (VRDN) in Q1 2026, valued at approximately $7.08 million based on average pricing. The move reduced the fund’s stake ahead of a key FDA decision on June 30.
The sale trimmed the position’s quarter-end value by $8.97 million, reflecting stock price movements. Viridian shares closed at $17.43 on May 14, 2026, up 35% year-over-year, outperforming the S&P 500’s 25% gain.
HighVista’s top holdings post-sale include DBC ($30.61 million), ABVX ($12.61 million), and PRAX ($8.48 million). Viridian focuses on monoclonal antibody therapies for thyroid eye disease.